MX2022015327A - Compuestos y metodos para el tratamiento de trastornos oculares. - Google Patents

Compuestos y metodos para el tratamiento de trastornos oculares.

Info

Publication number
MX2022015327A
MX2022015327A MX2022015327A MX2022015327A MX2022015327A MX 2022015327 A MX2022015327 A MX 2022015327A MX 2022015327 A MX2022015327 A MX 2022015327A MX 2022015327 A MX2022015327 A MX 2022015327A MX 2022015327 A MX2022015327 A MX 2022015327A
Authority
MX
Mexico
Prior art keywords
methods
compounds
treatment
eye disorders
reducing
Prior art date
Application number
MX2022015327A
Other languages
English (en)
Spanish (es)
Inventor
Darren Kelly
Michelle Papadimitriou
Chris Burns
Eric Daniels
Original Assignee
Occurx Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901856A external-priority patent/AU2020901856A0/en
Application filed by Occurx Pty Ltd filed Critical Occurx Pty Ltd
Publication of MX2022015327A publication Critical patent/MX2022015327A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2022015327A 2020-06-05 2021-06-03 Compuestos y metodos para el tratamiento de trastornos oculares. MX2022015327A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020901856A AU2020901856A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
AU2020901858A AU2020901858A0 (en) 2020-06-05 Compounds and Methods for the Treatment of Eye Disorders
PCT/US2021/035749 WO2021247900A1 (en) 2020-06-05 2021-06-03 Compounds and methods for the treatment of eye disorders

Publications (1)

Publication Number Publication Date
MX2022015327A true MX2022015327A (es) 2023-02-22

Family

ID=78829970

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015327A MX2022015327A (es) 2020-06-05 2021-06-03 Compuestos y metodos para el tratamiento de trastornos oculares.

Country Status (11)

Country Link
US (1) US20230270703A1 (cg-RX-API-DMAC7.html)
EP (1) EP4161527A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023529845A (cg-RX-API-DMAC7.html)
KR (1) KR20230024331A (cg-RX-API-DMAC7.html)
CN (1) CN116033901A (cg-RX-API-DMAC7.html)
AU (1) AU2021284380A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022024728A2 (cg-RX-API-DMAC7.html)
CA (1) CA3185849A1 (cg-RX-API-DMAC7.html)
IL (1) IL298733A (cg-RX-API-DMAC7.html)
MX (1) MX2022015327A (cg-RX-API-DMAC7.html)
WO (2) WO2021247901A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022238294A1 (en) * 2021-03-17 2023-10-05 Occurx Pty Ltd Compounds for the treatment of disorders and salts and polymorphs thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6339814A (ja) * 1986-08-01 1988-02-20 Teisan Seiyaku Kk トラニラストの経口用持続性製剤
NZ331339A (en) * 1996-02-15 2001-02-23 Kissei Pharmaceutical Neovascularization inhibitor comprising N-(3, 4-dimethoxycinnamoyl)anthranilic acid
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
IL132391A0 (en) * 1997-04-18 2001-03-19 Kissei Pharmaceutical Preventives or remedies for diseases effecting excessive proliferation or retinal pigment eptihelial cells
AU2002366641A1 (en) * 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CA2702984C (en) * 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
WO2010137681A1 (ja) * 2009-05-29 2010-12-02 参天製薬株式会社 トラニラストを含有する網膜疾患の予防または治療剤、網膜疾患の予防または治療方法、トラニラストまたはその医薬的に許容される塩、ならびにその使用
AU2011334592C1 (en) * 2010-11-24 2015-04-02 Occurx Pty Ltd Methods of treating eye diseases associated with inflammation and vascular proliferation
US10780070B2 (en) * 2013-10-18 2020-09-22 The Schepens Eye Research Institute, Inc. Alpha-aminoadipate for treatment of vision loss and restoring sight

Also Published As

Publication number Publication date
JP2023529845A (ja) 2023-07-12
IL298733A (en) 2023-02-01
KR20230024331A (ko) 2023-02-20
WO2021247900A1 (en) 2021-12-09
US20230270703A1 (en) 2023-08-31
WO2021247901A1 (en) 2021-12-09
EP4161527A4 (en) 2024-06-26
CN116033901A (zh) 2023-04-28
BR112022024728A2 (pt) 2023-03-07
EP4161527A1 (en) 2023-04-12
CA3185849A1 (en) 2021-12-09
AU2021284380A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
Sampat et al. Complications of intravitreal injections
Alio et al. Ten years after photorefractive keratectomy (PRK) and laser in situ keratomileusis (LASIK) for moderate to high myopia (control-matched study)
PH12015502587A1 (en) Opthalmic nanoemulsion composition containing cyclosporine and method for preparing same
CN114306575A (zh) 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
WO2012161655A1 (en) Composition and/or method for reducing and/or preventing myopia progression comprising atropine
Iqbal et al. Evaluation of the effectiveness of cross-linking combined with photorefractive keratectomy for treatment of keratoconus
Tian et al. Outcomes of corneal crosslinking for central and paracentral keratoconus
WO2019090010A3 (en) Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
Ma et al. Bilateral lateral rectus muscle recession for the convergence insufficiency type of intermittent exotropia
Tzamalis et al. Diode laser cyclophotocoagulation versus cyclocryotherapy in the treatment of refractory glaucoma
US20070254914A1 (en) Low-concentration atropine solution for preventing myopia progression and preparing method thereof
BR112022024728A2 (pt) Compostos e métodos para tratamento de distúrbios oftalmológicos
Esfahani et al. A review of the usage and post-surgical outcomes of anesthesia for laser in situ keratomileusis (LASIK) procedure
de Lima Neto et al. Micropulse versus slow coagulation transscleral cyclophotocoagulation in refractory glaucoma: A randomized clinical trial
Guzun et al. Efficacy of modified diode transscleral cyclophotocoagulation in patients with painful neovascular glaucoma secondary to retinal vein occlusion.
Ekdawi et al. Intravitreal triamcinolone and bevacizumab combination therapy for macular edema due to central retinal vein occlusion refractory to either treatment alone
O’Brart Corneal collagen cross-linking for corneal ectasias
Hasani et al. Trans-epithelial photorefractive keratectomy in the treatment of myopia, hyperopia and astigmatism: five-year results
Varman et al. Safety and efficacy of low-energy small incision lenticule extraction for the correction of myopia and myopic astigmatism: A retrospective analysis
US20190099401A1 (en) Method for protecting corneal endothelial cells from the impact caused by an eye surgery
Epstein et al. Indications, results, and complications of refractive corneal surgery with lasers
Nazar et al. Clinical Impact of Trans-Photorefractive Keratectomy and Femtosecond Laser In-Situ Keratomileusis in patients with Myopia and Astigmatism
Yadav et al. Inferior oblique Z‑myotomy for hypertropia correction in children
Mohamed et al. Laser In Situ Keratomileusis Retreatment with Wavefront-Optimized Technique after Primary Wavefront-Guided LASIK: Proof of Concept
Prabhakar et al. Combined Wavefront Guided on the Flap Photorefractive Keratectomy with Accelerated Collagen Cross-linking for Postlaser In situ Keratomileusis Ectasia: A Novel Technique